Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Operations (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash from Operations over the past 9 years, most recently at 92901000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 92901000.0 for Q4 2025, down 38.93% from a year ago — trailing twelve months through Dec 2025 was 377922000.0 (down 64.18% YoY), and the annual figure for FY2025 was 377922000.0, down 64.18%.
  • Cash from Operations for Q4 2025 was 92901000.0 at Crinetics Pharmaceuticals, up from 110718000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CRNX hit a ceiling of 13543000.0 in Q1 2022 and a floor of 110718000.0 in Q3 2025.
  • Median Cash from Operations over the past 5 years was 41072500.0 (2023), compared with a mean of 49025350.0.
  • Biggest five-year swings in Cash from Operations: skyrocketed 32.51% in 2022 and later plummeted 200.66% in 2023.
  • Crinetics Pharmaceuticals' Cash from Operations stood at 22899000.0 in 2021, then crashed by 53.75% to 35207000.0 in 2022, then dropped by 15.9% to 40806000.0 in 2023, then crashed by 63.88% to 66871000.0 in 2024, then plummeted by 38.93% to 92901000.0 in 2025.
  • The last three reported values for Cash from Operations were 92901000.0 (Q4 2025), 110718000.0 (Q3 2025), and 85851000.0 (Q2 2025) per Business Quant data.